Compartmentalisation of cAMP-dependent signalling by caveolae in the adult cardiac myocyte.
Cyclic AMP exhibits local (sarcolemmal) and global (cytosolic) patterns of signalling, allowing receptor-specific signals to be generated by a single second messenger. Here we determine whether caveolae, invaginated lipid rafts, are responsible for confining the beta(2) adrenoceptor (AR) cAMP signal to the sarcolemmal compartment. Myocytes were treated with the cholesterol-depleting agent methyl-beta-cyclodextrin (M beta C) to disrupt caveolae. Caveolae-containing membrane fractions were isolated by detergent-free sucrose gradient fractionation. Cell shortening and phosphorylation of the sarcoplasmic reticular protein phospholamban (PLB) and the myofilament protein troponin I (TnI) were measured in response to beta(2) AR stimulation (with salbutamol in the presence of 1 microM atenolol). Ser(16) phosphorylation of PLB (pPLB), Ser(22,23) phosphorylation of TnI (pTnI), and positive lusitropy were used as indices of global cAMP signals. The ability of M beta C to disrupt caveolae was confirmed by selective depletion of the buoyant membrane fractions of cholesterol and caveolin 3, the 2 essential components of caveolae. In control cells, no change in pPLB, pTnI or time to half relaxation was recorded with beta(2) AR stimulation (P>0.05), but following caveolar disruption a 60-70% increase in phosphorylation of both proteins was seen, accompanied by positive lusitropy (P<0.05). These data show for the first time that disrupting caveolae converts the sarcolemmal-confined cAMP signal associated with beta(2) AR stimulation to a global signal that targets proteins of the sarcoplasmic reticulum and myofilaments, with functional sequelae. The role of caveolae in spatial control of cAMP may be relevant to perturbation of beta AR signalling in cardiovascular disease.
Institute of Membrane and Systems Biology, University of Leeds, Leeds, LS2 9JT, UK. s.c.calaghan@leeds.ac.uk
Sarah
S
Calaghan
Lukasz
L
Kozera
Ed
E
White
D008841:Actin Cytoskeleton / Q000378:metabolism; D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000420:Albuterol / Q000494:pharmacology; D000818:Animals; D001262:Atenolol / Q000494:pharmacology; D002135:Calcium-Binding Proteins / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000378:metabolism; D021941:Caveolae / Q000378:metabolism*; D051243:Caveolin 2 / Q000378:metabolism; D051244:Caveolin 3 / Q000378:metabolism; D002784:Cholesterol / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism*; D003600:Cytosol; D008297:Male; D032383:Myocytes, Cardiac / Q000378:metabolism*; D010766:Phosphorylation / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D018343:Receptors, Adrenergic, beta-2 / Q000378:metabolism*; D012508:Sarcolemma / Q000378:metabolism*; D012519:Sarcoplasmic Reticulum / Q000378:metabolism; D015290:Second Messenger Systems / Q000187:drug effects; D019210:Troponin I / Q000378:metabolism; D000099211:Phospholamban
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D000420:Albuterol; D001262:Atenolol; D002135:Calcium-Binding Proteins; D051243:Caveolin 2; D051244:Caveolin 3; D002784:Cholesterol; D000242:Cyclic AMP; D018343:Receptors, Adrenergic, beta-2; D019210:Troponin I; D000099211:Phospholamban; C417736:CAV3 protein, human